Non-alcoholic Steatohepatitis (NASH) - Global Strategic Business Report

The global market for Non-alcoholic Steatohepatitis (NASH) was valued at US$12.8 Billion in 2024 and is projected to reach US$181.5 Billion by 2030, growing at a CAGR of 55.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Non-alcoholic Steatohepatitis (NASH) market.

Global Non-alcoholic Steatohepatitis (NASH) Market - Key Trends and Drivers Summarized

Why Is Non-Alcoholic Steatohepatitis (NASH) a Rising Global Health Crisis?

Non-alcoholic steatohepatitis (NASH) has rapidly emerged as a significant global health issue, driven largely by the rising incidence of obesity and type 2 diabetes worldwide. NASH is a more severe form of non-alcoholic fatty liver disease (NAFLD) and is characterized by liver inflammation and fibrosis, which can lead to cirrhosis, liver failure, and even liver cancer. Unlike other liver diseases, NASH is not associated with alcohol consumption but rather with metabolic risk factors such as insulin resistance and hyperlipidemia. The disease is often asymptomatic until it progresses to advanced stages, making early detection and intervention critical yet challenging. With millions of people at risk globally, NASH is poised to become the leading cause of liver transplants in the coming decades, particularly in regions where obesity and diabetes are most prevalent. The silent and progressive nature of NASH underscores the urgent need for increased awareness, better diagnostic tools, and effective treatments.

How Are Innovations in Diagnostics and Treatment Shaping the Future of NASH Management?

The management of NASH is undergoing a significant transformation, thanks to innovations in both diagnostics and treatment. Historically, diagnosing NASH has been difficult, often requiring invasive liver biopsies to confirm the presence of inflammation and fibrosis. However, the advent of non-invasive diagnostic technologies, such as elastography and advanced biomarker assays, is revolutionizing the way NASH is detected and monitored. These tools not only reduce the need for biopsies but also enable earlier and more accurate diagnosis, which is critical for timely intervention. On the treatment front, there is a burgeoning pipeline of drugs in development, targeting various pathways involved in NASH progression, including fibrosis, oxidative stress, and lipid metabolism. Some of these therapies have shown promising results in clinical trials, bringing hope that effective treatments may soon be available. These advancements are expected to greatly improve patient outcomes by halting or even reversing disease progression, thus reducing the burden of NASH on healthcare systems worldwide.

What Challenges Does the NASH Market Face and What Opportunities Lie Ahead?

While the NASH market holds immense potential, it is not without its challenges. One of the most significant hurdles is the high cost and complexity of developing effective NASH therapies. Given the heterogeneity of the disease, with its varying stages and underlying causes, finding a one-size-fits-all treatment has proven difficult. Moreover, the lack of approved therapies has led to an unmet need in the market, where patients have limited options beyond lifestyle modifications. Despite these challenges, there are several opportunities on the horizon. The growing understanding of the molecular mechanisms underlying NASH is paving the way for the development of targeted therapies that could offer more personalized and effective treatment options. Additionally, the increasing focus on early diagnosis and intervention is expanding the market for diagnostic tools and creating demand for therapies that can address the disease in its early stages. As awareness of NASH continues to rise, particularly among healthcare providers and at-risk populations, there is a growing market opportunity for both pharmaceutical and diagnostic companies.

What Factors Are Driving Growth in the NASH Market?

The growth in the NASH market is driven by several factors that reflect advancements in technology, shifts in patient demographics, and evolving healthcare practices. One of the primary drivers is the escalating prevalence of obesity and type 2 diabetes, which are strongly linked to the development of NASH. This expanding patient population is creating a significant demand for both diagnostic tools and therapeutic options. Additionally, innovations in non-invasive diagnostics are enabling earlier detection of NASH, which in turn increases the number of patients eligible for treatment and intervention. The robust pipeline of drugs under development, targeting various mechanisms of the disease, is another crucial factor driving market growth, with several candidates expected to receive approval and enter the market soon. Moreover, the trend towards personalized medicine is gaining traction in the NASH space, with therapies being developed to cater to specific patient subgroups, thereby improving efficacy and reducing adverse effects. The increasing awareness of NASH among healthcare professionals and patients is also contributing to market expansion, as early detection and treatment become more prioritized in clinical settings. Collectively, these factors are fueling the rapid growth of the NASH market, making it one of the most dynamic areas in the field of liver disease treatment.

Report Scope

The report analyzes the Non-alcoholic Steatohepatitis (NASH) market, presented in terms of units. The analysis covers the key segments and geographic regions outlined below.

Segments: Drug Type (Vitamin E & Pioglitazone, Obeticholic Acid (OCA), Elafibranor, Selonsertib & Cenicriviroc); Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy).

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Vitamin E & Pioglitazone segment, which is expected to reach US$59.7 Billion by 2030 with a CAGR of a 45.3%. The Obeticholic Acid (OCA) segment is also set to grow at 43.4% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $4.0 Billion in 2024, and China, forecasted to grow at an impressive 52.0% CAGR to reach $24.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Non-alcoholic Steatohepatitis (NASH) Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Non-alcoholic Steatohepatitis (NASH) Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Non-alcoholic Steatohepatitis (NASH) Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as 89bio, Akero Therapeutics, Arrowhead Pharmaceuticals, Inc., Belite Bio Inc., Boehringer Ingelheim International GmbH and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 12 companies featured in this Non-alcoholic Steatohepatitis (NASH) market report include:

• 89bio
• Akero Therapeutics
• Arrowhead Pharmaceuticals, Inc.
• Belite Bio Inc.
• Boehringer Ingelheim International GmbH
• Caldan Therapeutics Ltd
• Elixir Rx Solutions, LLC
• Gilead Sciences, Inc.
• Immuron Ltd.
• Intercept Pharmaceuticals, Inc.

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry